Search

Your search keyword '"Schumacher, C."' showing total 1,323 results

Search Constraints

Start Over You searched for: Author "Schumacher, C." Remove constraint Author: "Schumacher, C."
1,323 results on '"Schumacher, C."'

Search Results

1. Bulk-like magnetic properties in MBE-grown unstrained, antiferromagnetic CuMnSb

2. TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy

3. Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2− early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2− trial

5. CdTe-HgTe core-shell nanowire growth controlled by RHEED

6. Global energetics and local physics as drivers of past, present and future monsoons

9. Right ventricular outflow tract cardiomyocytes possess distinct calcium handling and contractile properties

10. Kinetic limitation of chemical ordering in Bi$_2$Te$_{3-x}$Se$_x$ layers grown by molecular beam epitaxy

11. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

12. The Green Ocean Amazon Experiment (GoAmazon2014/5) Observes Pollution Affecting Gases, Aerosols, Clouds, and Rainfall over the Rain Forest

13. Forschungsprojekt VAC-MAC - VACcinierung von MS/Arthritis/Colitis-Patient:innen (Teil 3) - Vergleich der Impfwirksamkeit zwischen MAC-Patient:innen und Nicht-MAC-Personen

14. Forschungsprojekt 'VAC-MAC - VACcinierung von MS/Arthritis/Colitis-Patient:innen' (Teil 2): Methodik zur Identifizierung von Einflussfaktoren auf die Impfinanspruchnahme auf der Grundlage von GKV-Routinedaten

15. Forschungsprojekt VAC-MAC - VACcinierung von MS/Arthritis/Colitis-Patient:innen (Teil 1): Wie können Einflussfaktoren aus GKV-Routinedaten gefiltert werden und welche Daten sind relevant?

16. Empirische Perspektiven auf die Akzeptanz, Implementierung und Versorgungseffekte von DiGA aus Sicht von Versicherten, Leistungserbringern, Krankenkassen und DiGA-Herstellern: Ergebnisse deutschlandweiter Fragebogenerhebungen

17. Wie kann die Versorgung mit DiGA bedarfsgerecht weiterentwickelt werden? Evidenzbasierte Empfehlungen auf Basis einer Analyse des aktuellen DiGA-Angebots und DiGA-Verzeichnisses sowie eines formellen Konsensfindungs-Workshops

18. Wie belastbar ist die Evidenz für positive Versorgungseffekte von DiGA? Ergebnisse eines Systematischen Reviews von DiGA-Zulassungsstudien

19. Wie können Versorgungseffekte von digitalen Gesundheitsanwendungen anhand von GKV-Routinedaten gemessen werden?

20. Suppressing twin formation in Bi2Se3 thin films

21. Removal of GaAs growth substrates from II-VI semiconductor heterostructures

22. Molecular beam epitaxy of high structural quality Bi2Se3 on lattice matched InP(111) substrates

24. Unravelling the signaling pathway downstream of the neurokinin receptor in atrium: discovering novel anti-arrhythmic targets for treatment of atrial fibrillation

25. Bloodstream infections in neonates with central venous catheters in three tertiary neonatal intensive care units in Pune, India

29. Aktuelles | aus der Landesarchäologie

30. SUPPLEMENT : THE GREEN OCEAN AMAZON EXPERIMENT (GOAMAZON2014/5) OBSERVES POLLUTION AFFECTING GASES, AEROSOLS, CLOUDS, AND RAINFALL OVER THE RAIN FOREST

31. De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel

33. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)

34. LBA14 Impact of age, recurrence score (RS) and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Analysis of ADAPT and ADAPTcycle trials

36. Bloodstream infections in neonates with central venous catheters in three tertiary neonatal intensive care units in Pune, India.

40. De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab +/- weekly paclitaxel (vol 28, pg 2768, 2017)

42. Corrigendum to “De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel”

48. LBA13 Predictive impact of biomarkers on pCR and survival after de-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs. trastuzumab+ET in HER2+/HR+ early breast cancer: WSG ADAPT TP trial

50. Unravelling Differences in Candidate Genes for Drought Tolerance in Potato (Solanum tuberosum L.) by Use of New Functional Microsatellite Markers

Catalog

Books, media, physical & digital resources